RhoA as a Mediator of Clinically Relevant Androgen Action in Prostate Cancer Cells
Lucy J. Schmidt(Mayo Clinic), Hannelore V. Heemers(Cleveland Clinic), Gregory E. Wilding(University at Buffalo, State University of New York), Christine M. Lohse(Quantitative BioSciences), Alissa R. Verone(Roswell Park Comprehensive Cancer Center), Thomas J. Sebo(Mayo Clinic), James L. Mohler, Kevin M. Regan(Mayo Clinic in Arizona), Elena Pop(Universitatea Națională de Știință și Tehnologie Politehnica București), Kelly Duncan(Roswell Park Comprehensive Cancer Center), Donald J. Tindall(Mayo Clinic), Neelu Yadav(HCG Cancer Centre), Kristopher Attwood(American College of Radiology)
Cited by 61
Related Papers
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Prostate Cancer
|Journal of the National Comprehensive Cancer Network|2010|902
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
|Proceedings of the National Academy of Sciences|2004|767
Prostate Cancer, Version 1.2016
|Journal of the National Comprehensive Cancer Network|2016|656
618: Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target
|The Journal of Urology|2005|387